Cytomegalovirus Infection Clinical Trial
Official title:
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
Despite the improvement of efficacy results with current immunosuppressive regimens (about
15% of incidence of acute rejection), the security schemes used do not show the same
results.The most worldwide used regime is tacrolimus, mycophenolate and prednisone. Despite
the favorable efficacy results in our population, the use of this combination is associated
with higher incidence of viral infections such as cytomegalovirus, and gastrointestinal
events, two common causes of hospital readmissions after renal transplantation at our
institution.Given this, the investigators propose a study of our own initiative that attends
our local needs: identify the best strategy among the therapeutic options available to
maintain the result of current effectiveness and improve the safety profile for kidney
transplant recipients.This protocol is a prospective, randomized, single center, designed to
compare the safety and efficacy of three immunosuppressive regimens: (1) single dose of
antithymocyte globulin, reduced exposure to tacrolimus, everolimus starting on day 2 after
transplantation and prednisone; ( 2) basiliximab, reduced exposure to tacrolimus, everolimus
starting on day 2 after transplantation and prednisone; (3-control group) basiliximab,
reduced exposure to tacrolimus, mycophenolate and prednisone.Our hypothesis is that a single
dose of antithymocyte globulin or basiliximab induction therapy in combination with low
doses of tacrolimus, everolimus and prednisone results in comparable efficacy observed in
patients receiving tacrolimus / mycophenolate / prednisone, but with a better safety
profile.
To ensure efficacy, the investigators added to the regimes the induction with monoclonal or
polyclonal antibody. To improve the toxicities associated with the current scheme, the
investigators replace the use of mycophenolate by everolimus and the investigators reduced
the dose of tacrolimus.
Patients will be monitored for blood levels of tacrolimus and everolimus to ensure adequate
exposure to immunosuppressive agents.
Primary end-point: The incidence of CMV infection or disease during the first year of
transplantation.Secondary main end-point: the incidence of treatment failure defined as a
composite end-point of BCAR, graft loss, death, loss to follow up.
The investigators anticipate enrolling 300 patients within 12 months. Only low risk adult
candidates for first renal transplants from living or deceased donors will be considered for
enrollment. Patients will be excluded if they have been receiving immunosuppressive therapy
before transplantation; have received an investigational medication within the past 30 days;
have a known contraindication to the administration of antithymocyte globulin; if tested
positive for human immunodeficiency virus (HIV); if had had cancer (except nonmelanoma skin
cancer) within the previous 2 years. Pregnant women, nursing mothers, and women of
childbearing potential who will be not using condoms or oral contraceptives will be
excluded. Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or
class II, will also be excluded. Study visits will be performed at pre transplant, days 0,
1, 7, every week up to month 6 and month 12.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00023036 -
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
|
||
Terminated |
NCT01037712 -
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
|
Phase 4 | |
Completed |
NCT00370006 -
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
|
Phase 1 | |
Completed |
NCT01552369 -
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
|
Phase 4 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT00223925 -
Maribavir for Prevention of CMV After Stem Cell Transplants
|
Phase 2 | |
Active, not recruiting |
NCT05085366 -
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
|
Phase 3 | |
Completed |
NCT01220895 -
Alternate Donor Study of Pre-Emptive Cellular Therapy
|
Phase 2 | |
Completed |
NCT00942305 -
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Completed |
NCT00373412 -
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
|
Phase 1 | |
Completed |
NCT05105048 -
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
|
Phase 1 | |
Completed |
NCT00386412 -
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
|
Phase 2 | |
Completed |
NCT03382405 -
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
|
Phase 1 | |
Completed |
NCT02454699 -
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03910478 -
Dried Blood Spot Testing of CMV Detection in HCT Recipients
|
N/A | |
Active, not recruiting |
NCT01473849 -
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00880789 -
Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus
|
Phase 1 | |
Completed |
NCT00817908 -
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
|
N/A | |
Completed |
NCT00273143 -
A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
|
Phase 1 | |
Completed |
NCT00194155 -
Cytomegalovirus (CMV) Infection in Pregnancy
|
N/A |